Overview

Nateglinide: a Double Blind Add-on Study With Pioglitazone for Type 2 Diabetic Patients

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the superiority of nateglinide over placebo for inadequately controlled type 2 diabetic patients with pioglitazone treatment.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Astellas Pharma Inc
Collaborator:
Ajinomoto USA, INC.
Treatments:
Nateglinide
Pioglitazone